Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFlorida AHCA Trikafta Prior Auth Coverage | OpenPa…
    Ask Trek AI about this page
    CurrentAgency for Health Care AdministrationPolicy N/A

    Trikafta Prior Authorization Coverage

    Customize your policy alerts

    Sign up for all Agency for Health Care Administration policy alerts

    Know when Agency for Health Care Administration releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for Trikafta for patients with cystic fibrosis, including initial approval criteria, continuation requirements, monitoring documentation, and authorization periods up to six months.

    Policy Summary
    PayerAgency for Health Care Administration
    PolicyTrikafta Prior Authorization Coverage
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateSep 17, 2021
    Next Review DateN/A
    Key ActionSubmit documentation confirming cystic fibrosis, a qualifying CFTR mutation, and required baseline monitoring for initial authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≤6 moMaximum authorization duration
    ≥2 yrMinimum initial age
    ≥1 mutationGenetic eligibility
    ≥2Response measures for continuation
    3 mo → annual

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Liver test monitoring

    Coverage Criteria

    Initial Therapy

    Covered for initial therapy when all of the following are met.

    Initial therapy requirements

    • Patient eligibility

      • Age: Patient is at least 2 years old.≥2 years
      • Diagnosis: Patient has cystic fibrosis confirmed through health condition documentation or medical records.
      • Qualifying CFTR mutation

        • Patient has at least one F508del mutation in the CFTR gene.≥1 F508del mutation
        • Patient has a mutation in the CFTR gene that is responsive to Trikafta based on in vitro data.
        • If the patient's genotype is unknown, an FDA-cleared CF mutation test confirms at least one F508del mutation or a CFTR mutation responsive based on in vitro data.

          Required when genotype is unknown.

      • Baseline monitoring

        • Baseline liver function tests are completed before initiating therapy.
        • For patients ages 2 to less than 18 years, a baseline ophthalmic examination is completed to monitor for lens opacities or cataracts.Age 2 to <18 years
        • For patients age 6 years or older, baseline percent predicted FEV1 is documented from within the previous 90 days.Age ≥6 years; within previous 90 days

    Continuation Therapy

    Covered for continuation when all of the following are met.

    Continuation therapy requirements

    • Disease response

      • Decreased pulmonary exacerbations compared with the pretreatment baseline.
      • Improvement or stabilization of lung function measured by percent predicted FEV1 compared with baseline, or a decreased rate of lung-function decline.
      • Improvement toward the patient's target BMI or maintenance of target BMI.
      • Clinical notes document improvement of patient symptoms.
    • Patient has not received a lung transplant.

    Patients who have received a lung transplant are not eligible for continuation therapy.

    Patients who have experienced unacceptable toxicity from Trikafta are not eligible for continuation therapy.

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Prior Authorization Required

    Prior authorization is required for initial Trikafta therapy. Approval is available for patients meeting the clinical and documentation requirements below; authorization may be issued for up to 6 months.

    • Patient is at least 2 years old.
    • Cystic fibrosis diagnosis is confirmed through the health condition or medical records.
    • Patient has at least one F508del mutation in the CFTR gene or a CFTR mutation responsive based on in vitro data.
    • If genotype is unknown, submit results from an FDA-cleared CF mutation test confirming at least one F508del or in-vitro-responsive mutation.
    • Submit baseline liver function tests before therapy begins.
    • For patients ages 2 to <18 years, submit a baseline ophthalmic examination to monitor for lens opacities or cataracts.
    • For patients at least 6 years old, submit baseline documented percent predicted FEV1 obtained within the previous 90 days.
    Prior Authorization

    Therapy Background

    Trikafta (elexacaftor, tezacaftor, and ivacaftor) is a combination CFTR modulator used to treat cystic fibrosis. Coverage is limited to patients with cystic fibrosis who have at least one qualifying CFTR mutation—an F508del mutation or another mutation shown to be responsive to Trikafta based on in vitro data. If the patient’s genotype is unknown, an FDA-cleared CF mutation test must confirm qualifying genetic eligibility.

    Definitions

    Definitions
    DefinitionA CFTR mutation that has demonstrated responsiveness to Trikafta based on in vitro data.
    Qualifying criterionAt least one F508del mutation or a CFTR mutation responsive to Trikafta based on in vitro data qualifies for initial therapy.
    Unknown genotypeIf the patient’s genotype is unknown, an FDA-cleared CF mutation test should confirm at least one F508del mutation or an in-vitro-responsive CFTR mutation.
    Definitions
    DefinitionForced expiratory volume in one second expressed as a percentage of the predicted value for the patient.
    Age requirementBaseline percent predicted FEV1 is required for patients age 6 years and older.

    Initial Therapy Criteria

    Initial Therapy

    Initial therapy requires all of the following age, diagnosis, genotype, and baseline monitoring criteria.

    Initial therapy

    • Patient is at least 2 years old.≥2 years
    • Patient has cystic fibrosis confirmed through health condition documentation or medical records.
    • Qualifying CFTR mutation

      • At least one F508del mutation is present in the CFTR gene.≥1 F508del mutation

    Continuation Therapy Criteria

    Continuation Therapy

    Continuation therapy requires all of the following.

    Continuation requirements

    • Disease response

      • Decreased pulmonary exacerbations compared with the pretreatment baseline.
      • Improvement or stabilization of lung function, measured by percent predicted FEV1 compared with baseline, or a decreased rate of decline of lung function.
      • Improvement toward the patient's target BMI or maintenance of target BMI.
      • Clinical notes document improvement of patient symptoms.
    Policy Summary
    PayerAgency for Health Care Administration
    PolicyTrikafta Prior Authorization Coverage
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateSep 17, 2021
    Next Review DateN/A
    Key ActionSubmit documentation confirming cystic fibrosis, a qualifying CFTR mutation, and required baseline monitoring for initial authorization.
    SourceLink
    On This Page
    Coverage CriteriaAuthorization and Documentation RequirementsTherapy BackgroundDefinitionsInitial Therapy CriteriaContinuation Therapy Criteria

    Patients who have received a lung transplant are not eligible for continuation therapy.

  1. Patient has not experienced unacceptable toxicity from Trikafta.

    Patients who have experienced unacceptable toxicity from Trikafta are not eligible for continuation therapy.

  2. Submit liver function tests every three months with the initial reauthorization and one liver function test annually thereafter.Every 3 months with initial reauthorization; annually thereafter
  3. For patients ages 2 to less than 18 years, obtain a follow-up ophthalmic examination at least annually.Age 2 to <18 years; at least annually
  4. Reauthorization for Continuation Therapy

    Reauthorization is required for continuation of therapy. Submit documentation demonstrating disease response, required safety monitoring, and continued eligibility. Each authorization may be approved for up to 6 months.

    • Document disease response using at least two qualifying response measures.
    • Patient must not have received a lung transplant.
    • Patient must not have experienced unacceptable toxicity from Trikafta.
    • Submit liver function tests every 3 months with the initial reauthorization, followed by at least one liver function test annually thereafter.
    • For patients ages 2 to <18 years, submit a follow-up ophthalmic examination at least annually.
    Documentation Required

    Initial Clinical and Laboratory Documentation

    Submit clinical and laboratory documentation supporting the initial request. The record must confirm cystic fibrosis, a qualifying CFTR mutation, and all required baseline assessments before treatment begins.

    • Confirm cystic fibrosis through the health condition or medical records.
    • Document at least one F508del mutation or an in-vitro-responsive CFTR mutation; when genotype is unknown, provide an FDA-cleared CF mutation test result.
    • Provide baseline liver function tests before initiation.
    • For ages 2 to <18 years, provide a baseline ophthalmic examination.
    • For patients at least 6 years old, provide percent predicted FEV1 documented within the prior 90 days.
    Documentation Required

    Continuation Monitoring Documentation

    Continuation requests must include the required safety and monitoring documentation. Monitoring requirements apply in addition to documentation of clinical response.

    • Submit liver function tests every 3 months with the initial reauthorization.
    • After the initial reauthorization, submit at least one liver function test annually.
    • For patients ages 2 to <18 years, submit a follow-up ophthalmic examination at least annually.
    Documentation Required

    Response Documentation Required

    Document disease response for continuation authorization using at least two of the following measures compared with pretreatment or baseline status.

    • Decreased pulmonary exacerbations compared with pretreatment baseline.
    • Improvement or stabilization of lung function measured by percent predicted FEV1, or a decreased rate of lung-function decline.
    • Improvement toward the patient's target BMI or maintenance of target BMI.
    • Clinical notes documenting improvement in patient symptoms.
    Denial Risk

    Failure to Meet Initial Criteria

    The initial request should be denied when the patient does not meet the age, diagnosis, mutation, or baseline documentation requirements for Trikafta.

    • Patient is younger than 2 years old.
    • Cystic fibrosis is not confirmed through the health condition or medical records.
    • No F508del or in-vitro-responsive CFTR mutation is documented, including when required FDA-cleared testing is absent for an unknown genotype.
    • Required baseline liver function tests are not provided.
    • For ages 2 to <18 years, the baseline ophthalmic examination is missing.
    • For patients at least 6 years old, percent predicted FEV1 from within the previous 90 days is not documented.
    Denial Risk

    Failure to Meet Continuation Criteria

    Continuation authorization should be denied when required response, eligibility, safety, or monitoring criteria are not met or documented.

    • Fewer than two qualifying disease-response measures are documented.
    • Patient has received a lung transplant.
    • Patient has experienced unacceptable toxicity from Trikafta.
    • Required liver function tests are not submitted on the specified schedule.
    • For patients ages 2 to <18 years, the required annual follow-up ophthalmic examination is not documented.
    TimingThe baseline percent predicted FEV1 must be documented within the previous 90 days before initiating therapy.
    A CFTR gene mutation is present that is responsive to Trikafta based on in vitro data.
  5. If the patient's genotype is unknown, an FDA-cleared CF mutation test confirms at least one F508del mutation or a mutation responsive based on in vitro data.

    Use the FDA-cleared test when genotype is unknown.

  6. Baseline monitoring

    • Baseline liver function tests are completed before therapy is initiated.
    • Patients ages 2 to less than 18 years have undergone a baseline ophthalmic examination to monitor lens opacities or cataracts.Age 2 to <18 years
    • Patients age 6 years or older have documented baseline percent predicted FEV1 obtained within the previous 90 days.Age ≥6 years; within previous 90 days
  7. Patient has not received a lung transplant.

    Receipt of a lung transplant excludes continuation therapy.

  8. Patient has not experienced unacceptable toxicity from Trikafta.

    Unacceptable toxicity from Trikafta excludes continuation therapy.

  9. Liver function tests are submitted every three months with the initial reauthorization and annually thereafter.Every 3 months initially; annually thereafter
  10. Patients ages 2 to less than 18 years have a follow-up ophthalmic examination at least annually.Age 2 to <18 years; at least annually